Prevest Denpro Ltd
Prevest Denpro Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
1 of 3 strong
The short version
The US business is expected to grow significantly over the next 2-3 years, driven by private labeling and online sales, with aggressive participation in US exhibitions. The company demonstrated steady growth with a 13.9% increase in revenue and 12.9% growth in profit after tax for FY 2025-26.
From Prevest Denpro Ltd's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- The US business is expected to grow significantly over the next 2-3 years, driven by private labeling and online sales, with aggressive participation in US exhibitions.
- Digital dentistry revenue, especially 3D printing resins, grew 40% this year; 3D printer sales rose by 162%, indicating strong growth potential, with plans for an indigenous 3D printer by 2028.
- Export markets are expected to expand with new international market entries and subsidiaries in the USA and UAE contributing to growth.
- Domestic sales are projected to increase through expanded distribution in Tier 2 and Tier 3 cities and enhancing sales team strength.
- New product launches in the Oradox oral health segment and disinfectants business anticipate boosting revenues.
2 more points from Prevest Denpro Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Prevest Denpro Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Prevest DenPro is actively investing in the development of a fully indigenous 3D printer, targeting commercialization by 2028, enhancing their digital dentistry portfolio.
- The company is expanding its disinfectant business vertical, with plans to invest in broadening its product portfolio in a disciplined, phased manner over the coming years.
- Continuous investment is being made in advanced digital solutions and research and development to strengthen leadership in digital dentistry.
- The company is working on import substitution for key raw materials, reducing dependency on foreign suppliers, which is part of their capital and R&D efforts.
2 more points from Prevest Denpro Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Equipment & Supplies
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Prevest Denpro Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Prevest Denpro Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Prevest Denpro Ltd — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹19 Cr, net profit ₹6 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Prevest Denpro's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- Avience Biomedicals Ltd (Q1 FY27)
New manufacturing facility has capacity to support peak revenue of around ₹250–265 crore, subject to product mix and approvals. Key concall takeaways from…
- Molbio Diagnosti (Q1 FY27)
Capacity utilization currently at ~58% for test kits and ~42% for devices; automation capex will double revenue capacity with minimal new investment. Key…
- QMS Medical Allied Services Ltd (Q1 FY27)
Contract renewals historically exhibit a 60-70% roll-over rate annually, ensuring revenue visibility from existing clients. Key concall takeaways from QMS…
- Laxmi Dental Ltd (Q1 FY27)
PAT grew 23.8% y-o-y in Q1 FY27, showing healthy bottom-line growth (Page 4). Key concall takeaways from Laxmi Dental Ltd's Q1 FY27 earnings call — and how it…
Arthneeti Pro · Annual
Prevest Denpro Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Prevest Denpro Ltd Q1 FY27 results?
The US business is expected to grow significantly over the next 2-3 years, driven by private labeling and online sales, with aggressive participation in US exhibitions. The company demonstrated steady growth with a 13.9% increase in revenue and 12.9% growth in profit after tax for FY 2025-26.
What is Prevest Denpro Ltd share price analysis?
Prevest Denpro Ltd currently shows a below-average growth signal. The stock trades at a P/E of 21.4 with a market cap of ₹458 Cr. Investors should review the full earnings analysis for detailed insights.
Is Prevest Denpro Ltd planning capital expenditure?
Prevest DenPro is actively investing in the development of a fully indigenous 3D printer, targeting commercialization by 2028, enhancing their digital dentistry portfolio. - The company is expanding its disinfectant business vertical, with plans to invest in broadening its product portfolio in a disciplined, phased manner over the coming years. - Continuous investment is being made in advanced digital solutions and research and development to strengthen leadership in digital dentistry. - The company is working on import substitution for key raw materials, reducing dependency on foreign suppliers, which is part of their capital and R&D efforts. - Subsidiaries in the UAE and the U.S.
Keep Prevest Denpro Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.